Ariel Fernandez May Have Created a WaterMap Precursor in 2007

Contributed by Weishi L. Meng, reproduced from Science Transparency.    Drug designers often implement molecular therapies to block malfunctioning proteins that are causing disease. They do so by creating small molecules that bind to the intended protein target when suitably delivered. The procedure has its risks as unintended targets (off-target proteins) may also be hit or […]

Structure-based drug discovery without structure: Working around the paradox to cure heart failure

Transcript on presentation by Ariel Fernandez for Drug Discovery Today (doi:10.1016/j.drudis.2015.10.006) Drug discovery has been focusing for some time on protein-protein (PP) associations, the basic molecular events in biology. The recruitment of protein complexes is required to initiate and propagate signaling cascades, regulate enzyme activity, articulate and control mechanistic processes involving molecular motors, etc. When […]

Ariel Fernandez at the Center of a Biotechnological Transformation (Reproduced from Science Transparency)

Interview reproduced from Science Transparency. Ariel Fernandez (also styled as Ariel Fernandez Stigliano) is a physical chemist and mathematician and the former Karl F. Hasselmann Endowed Chair Professor of Bioengineering at Rice University. He got his Ph. D. in record time from Yale University under the guidance of Oktay Sinanoglu (who recently passed away according to Yale News). Completed in less than two […]

Book Critique: “Transformative Concepts for Drug Design: Target Wrapping”

The pharmaceutical world has been in a state of disarray for quite a while. With most low-hanging fruits already picked, drug discovery seems riskier and more uncertain than ever. Projects often get terminated in mid-stage clinical trials, new targets are getting harder to find, and successful therapeutic agents are often recalled as unanticipated side effects […]